DR. PAUL W. GONTER M.D. NPI 1295726933

NPI Details

DR. Paul W. Gonter, M.D. is a medical oncology internal medicine in Venice, FL. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. DR. Paul W. Gonter, M.D. NPI is 1295726933. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

836 SUNSET LAKE BLVD
SUITE 101
VENICE, FL
ZIP 34292-554
Phone: (941) 408-0500
Fax: (941) 496-8558

The NPI 1295726933 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, rituximab, 10 mg (HCPCS:J9312)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Ferritin (blood protein) level (HCPCS:82728)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Iron level (HCPCS:83540)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Transferrin (iron binding protein) level (HCPCS:84466)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• Protein measurement, serum (HCPCS:84165)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Ct scan of chest with contrast (HCPCS:71260)
• Folic acid level, serum (HCPCS:82746)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection, methylprednisolone sodium succinate, up to 40 mg (HCPCS:J2920)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Iron binding capacity (HCPCS:83550)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Magnesium level (HCPCS:83735)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection of drug or substance into vein (HCPCS:96374)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Ct scan of chest without contrast (HCPCS:71250)
• Erythropoietin (protein) level (HCPCS:82668)
• Uric acid level, blood (HCPCS:84550)
• Urinalysis, manual test (HCPCS:81002)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Drawing of blood for a medical problem (HCPCS:99195)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Ct scan of abdomen and pelvis without contrast (HCPCS:74176)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Ct scan of soft tissue of neck with contrast (HCPCS:70491)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Ct scan of abdomen and pelvis before and after contrast (HCPCS:74178)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)

The enumeration date for this NPI number is 11/2/2005 and was last updated on 5/3/2022.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.